Malaria Vaccines Market Overview
More than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest share of global malaria burden, with around 89% of malaria cases and 91% of malarial deaths in 2015. Such high impact of this life threatening disease is influencing governments across various countries, companies, investors, and non-profit organizations to contribute towards curbing spreading of this disease. Treatment therapies include Artemisinin-based combination therapies (ACTs), chloroquine, and primaquine. Recurrence of this disease can lead to drug resistance and in severe cases can prove fatal. Therefore, prevention is the major focus of government, researchers, and drug companies. The World Health Organization (WHO) estimates that increase in prevention control and other measures has led to 60% reduction in malaria mortality since 2000. High prevalence and preventive measures initiated by global and national organizations would favor growth of the global malaria vaccines market.
To know the latest trends and insights prevalent in the Malaria Vaccines Market, click the link below:
Mosquirix – the First Malaria Vaccine in the Global Malaria Vaccines Market
Most major drug manufacturers have been constantly striving to develop a vaccine for this deadly disease. Among the pioneers in this field is GlaxoSmithKline, which has been working towards developing a malaria vaccine since 1984. In collaboration with the non-profit PATH Malaria Vaccine Initiative and funding from Bill & Melinda Gates Foundation, GlaxoSmithKline developed the first malarial vaccine.
Mosquirix, also known as RTS,S, was in development for around 30 years, with an investment of around US$ 565 million. Bill and Melinda Gates Foundation contributed over US$ 200 million towards this project. Mosquirix received marketing approval from the European authorities in July 2015. However, the WHO has recommended examination of the vaccine in a pilot study before introduction on a large scale. The study is being carried out in Africa, and has received a funding of US$ 25 million from Gavi—a global Vaccine Alliance—bringing together public and private sectors towards a common goal. Successful trials will lead to global launch of Mosquirix and boost the malaria vaccines market size.
Get Free PDF Brochure for more Professional and Technical Insights at https://www.coherentmarketinsights.com/insight/request-sample/37
Significant Potential for Malaria Vaccines Market in Africa, Latin America and Asia
Malaria vaccine seems to be the best solution to prevent the spread of malaria, especially considering increasing number of drug resistance cases and high fatality reported. People use bed nets and indoor residual spraying (IRS) to fight against mosquito infestation. Therefore, there is immense opportunity globally for malaria vaccines among the demographic group most at risk—infants (23 million births annually), pre-adolescent and early adolescent girls, pregnant women in sub-Saharan Africa, and population in Asia, Latin America, Africa, and Oceania. Furthermore, risk of transmission of the disease increases from the ‘traveller’ and military population travelling from the U.S., Europe, Japan, and Australia, a malaria free zone to the highly prone emerging economies. The global malaria vaccines market dynamics are mainly shaped by major purchasers, namely healthcare and non-profit organizations.
Ask for Complete Table of Contents (TOC) at https://www.coherentmarketinsights.com/ongoing-insight/toc/37
Malaria Vaccines Market Future Outlook
Mosquirix is a great boon for population in the highly prone regions of malaria infection. However, accessibility and low cost of this vaccine is essential to serve the large population in the highly prone emerging economies. Sanaria Inc. is a biotechnology company which aims to develop and commercialize whole-parasite sporozoite vaccines against Plasmodium falciparum that causes 95% of malaria cases. Mymetics Corporation—a Switzerland-based vaccines developer—uses its virosome platform technology to develop vaccines. There are two vaccine candidates in its pipeline, of which one cleared the phase 1b clinical trail, while the other is in the preclinical stage. Moreover, use of new technologies such as Nucleic acid vaccines, Proteosomes, and several new adjuvants could lead to development of next-generation malaria vaccines.
Such global commitments will encourage investors around the world to contribute towards a global malaria eradication mission. Further, the malaria vaccines market outlook for future holds much promise, with new vaccines being developed mainly focused on improving effectiveness of products.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights